uniQure (NASDAQ:QURE – Get Rating) VP Alexander Edward Kuta III sold 2,306 shares of the firm’s stock in a transaction on Wednesday, September 21st. The stock was sold at an average price of $18.65, for a total value of $43,006.90. Following the completion of the transaction, the vice president now owns 92,890 shares of the company’s stock, valued at approximately $1,732,398.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Alexander Edward Kuta III also recently made the following trade(s):
- On Thursday, July 28th, Alexander Edward Kuta III sold 27,358 shares of uniQure stock. The shares were sold at an average price of $25.00, for a total value of $683,950.00.
- On Friday, July 22nd, Alexander Edward Kuta III sold 5,643 shares of uniQure stock. The shares were sold at an average price of $25.00, for a total value of $141,075.00.
uniQure Stock Performance
Shares of QURE traded down $0.29 during mid-day trading on Friday, hitting $17.30. 595,818 shares of the company’s stock were exchanged, compared to its average volume of 620,248. The firm has a market capitalization of $808.41 million, a P/E ratio of -7.02 and a beta of 1.08. uniQure has a fifty-two week low of $12.52 and a fifty-two week high of $36.55. The business’s 50 day moving average is $21.24 and its two-hundred day moving average is $18.26. The company has a current ratio of 10.84, a quick ratio of 10.78 and a debt-to-equity ratio of 0.21.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. acquired a new position in uniQure in the 1st quarter valued at approximately $27,000. Captrust Financial Advisors increased its stake in shares of uniQure by 1,392.3% during the 2nd quarter. Captrust Financial Advisors now owns 1,940 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 1,810 shares during the last quarter. US Bancorp DE increased its stake in shares of uniQure by 108.2% during the 2nd quarter. US Bancorp DE now owns 1,978 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 1,028 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of uniQure by 152.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 1,231 shares during the last quarter. Finally, Covestor Ltd acquired a new position in uniQure in the 1st quarter valued at $50,000. Institutional investors own 86.46% of the company’s stock.
Analysts Set New Price Targets
QURE has been the subject of several recent analyst reports. Wells Fargo & Company cut their price target on uniQure from $34.00 to $24.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 9th. StockNews.com lowered uniQure from a “hold” rating to a “sell” rating in a research note on Wednesday, August 10th. Chardan Capital cut their price target on uniQure from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Tuesday, August 9th. Finally, TheStreet lowered uniQure from a “c-” rating to a “d” rating in a research note on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.38.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.
- Get a free copy of the StockNews.com research report on uniQure (QURE)
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.